Physician profile
Christopher Reist
NPI 1114972551
$12,052.91
in general payments reported to CMS, 2019-2025
11 companies · $34.61 in 2025
The $34.61 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,507 · 2020: $71.94 · 2021: $27.86 · 2022: $149 · 2024: $4,263 · 2025: $34.61.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,231 · Food and Beverage: $67.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,230.51 |
| Food and Beverage | $67.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| H. Lundbeck A S | $4,473.65 | 2019 | |
| Boehringer Ingelheim International Gmbh | $4,230.51 | 2024 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $3,178.76 | 2019-2024 | |
| Sunovion Pharmaceuticals INC. | $83.35 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $34.61 | 2025 | Caplyta |
| Lundbeck LLC | $27.86 | 2021 | |
| Avanir Pharmaceuticals, INC. | $24.17 | 2020 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Reist listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.